Components of a Humira autoinjector pen. There is strong evidence that<unk>  increases risk of serious infections, such as tuberculosis, and it has also been reported to increase the risk of developing various cancers. However, such an association may reflect an increased risk of developing malignancies inherent in the conditions being treated, and not with<unk>  itself. A systematic review published in 2018, found no increased cancer incidence rate in patients with chronic inflammatory disorders treated with<unk>  and other TNF inhibitors, as compared to those who were not, with a possible exception for non-melanoma skin cancer. There are rare reports of serious liver injury; rare reports of demyelinating central nervous system disorders; and rare reports of cardiac failure—the US Food and Drug Administration (FDA) issued a black box warning to doctors, which appears in the product labeling of<unk>  and other TNF-inhibiting drugs, instructing them to screen and monitor potential patients more carefully. Anaphylaxis or other serious allergic reactions may also occur.
Adalimumab
Etanercept
Belatacept
Abatacept
Tofacitinib
Sarilumab
Rituximab
Ruxolitinib